Orphazyme is pleased to announce that Dr. Georges Gemayel has been appointed Chairman of the Board of Directors.
Dr. Gemayel’s competences as an experienced pharmaceutical and biotechnology company executive with extensive industry expertise in the rare disease space will be instrumental to establishing Orphazyme ApS as a leading development company in the orphan disease area. Dr Gemayel joined the Orphazyme Board of Directors in March 2013. Dr Gemayel says: “I am looking forward to continuing the exciting work with Orphazyme as we pursue the next major milestone of showing clinical evidence of the potential of heat-shock protein based therapy for lysosomal storage diseases and other severe degenerative diseases of high unmet need.”
Martin Bonde, who has served as Chairman of the Board since 2010, will remain on the Board of Directors. Martin Bonde says: ”Orphazyme now has two programs in, or reaching, the clinical stage. I am pleased to be able to continue on the Board of Orphazyme while also fulfilling my obligations as CEO of Epitherapeutics. It is rewarding to be part of two such active and innovative Biotech companies.”
Anders Hinsby, CEO of Orphazyme ApS, says: “Orphazyme has now completed preclinical development of Orph-001, the recombinant version of HSP70, which is ready for Phase I development. At the same time, we have seen very promising in vivo data from our small molecule program of heat shock protein inducers, Orph-002, over the last six months. We now face the exciting but demanding task of taking two programs into and through clinical development and I am therefore satisfied that we maintain a strong Board of industry professionals.”
Kim Dueholm, Partner Novo Ventures, says: ”The shareholders are very pleased that Georges Gemayel has accepted to become Chairman of the Board and look forward to continuing the fruitful collaboration in this promising company. We are also pleased that Martin Bonde remains on the board and we wish to thank Martin Bonde for his outstanding contribution as Chairman to the development of Orphazyme.”
Anders Hinsby, CEO of Orphazyme
Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal. Orphazyme has raised more than 17 million euro in seed and series A financing, from a strong investor base which includes Novo Ventures, Sunstone Capital and Aescap Venture. For more information, please visit www.orphazyme.com.